# Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Study · id `cardio:ct-nct01999218` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01999218](<https://clinicaltrials.gov/study/NCT01999218>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01999218

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1326 participants.

## Technical summary

Registry record NCT01999218. Randomized; double masking; primary purpose treatment. Start 2013-12-16 (actual); primary completion 2017-04-18 (actual). Results posted on 2018-05-11.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1326 participants (enrolled count; ClinicalTrials.gov record NCT01999218, source copy `cardio:ctgov-nct01999218-2019-04-02`, retrieved 2026-10-26)
- Started: 2013-12-16 (actual) (ClinicalTrials.gov record NCT01999218, source copy `cardio:ctgov-nct01999218-2019-04-02`, retrieved 2026-10-26)
- Primary completion: 2017-04-18 (actual) (ClinicalTrials.gov record NCT01999218, source copy `cardio:ctgov-nct01999218-2019-04-02`, retrieved 2026-10-26)
- Completion: 2017-04-18 (actual) (ClinicalTrials.gov record NCT01999218, source copy `cardio:ctgov-nct01999218-2019-04-02`, retrieved 2026-10-26)
- Results first posted: 2018-05-11 (ClinicalTrials.gov record NCT01999218, source copy `cardio:ctgov-nct01999218-2019-04-02`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01999218-2019-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ertugliflozin 5 mg
- Intervention (Drug): Ertugliflozin 10 mg
- Intervention (Drug): Glimerpiride
- Intervention (Drug): Placebo to Ertugliflozin
- Intervention (Drug): Placebo to Glimepiride
- Intervention (Drug): Metformin
- Intervention (Drug): Sitagliptin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin (`cardio:pubmed-30760125`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b9f954266e9fa714f2d1d0fd93f952f11e93622b4865167e32e34ffcbe0cd4ed
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
